{"id":"https://genegraph.clinicalgenome.org/r/6996804b-6864-40e6-a88d-8a5800e91881v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between DBT and maple syrup urine disease (autosomal recessive) was evaluated using the ClinGen Clinical Validity Framework as of October, 2018. Variants in DBT were first reported in humans with the disease as early as 1991 (Herring et al., PMID: 1990841). At least 11 variants (missense, nonsense, frameshift, deletions) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. About 20% of MSUD cases are attributed to variants in this gene (Strauss et al., 2013; PMID: 20301495). More evidence is available in the literature, but the maximum score for genetic evidence and experimental evidence (18 pts.) has been reached. In summary, DBT is definitively associated with autosomal recessive maple syrup urine disease. This has been repeatedly demonstrated in both the research and clinical diagnostic\nsettings, and has been upheld over time. This classification was approved by the ClinGen Aminoaciopathy Gene Curation Expert Panel on 10/30/18 (SOP Version 5).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6996804b-6864-40e6-a88d-8a5800e91881","GCISnapshot":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2018-10-30T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/37a63a97-3621-491a-8143-acc4cb23afaa_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The deletion includes the 3' half of intron 10, the entire coding region of the terminal exon 11, and the 5' part of the 3' UTR of DBT.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f66c6201-a3ab-4736-ae26-519a49e32503","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24486081","rdfs:label":"Hou 2016 Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":7,"detectionMethod":"Direct sequencing and duplex PCR of DBT.","phenotypeFreeText":"Recurrent skin lesions, Zinc deficiency, Acrodermatitis enteropathica-like skin lesions, Bulging fontanelle, Twitching of limbs, Elevated Î±-hydroxyisovalerat, Elevated 2-hydroxyisovaleric, Elevated 3-hydroxyisovaleric, Elevated 2-hydroxy-3-methylvaterate, Abnormal faint bilateral hemisphere echogenicity, Progressive scaling over body, Topical corticosteroid resistant periorificial and acral dermatitis, Cortical dysfunction, Recurrent skin rash, Wedging deformity of T11 and T12 vertebrae, Retropulsion of posterior bony margins, Hyperintensity, Swelling, enlargement of left hemisphere, Asymmetry, Prominent cisterns, Sulci of bilateral hemispheres, Brain signal changes.","phenotypes":["obo:HP_0001943","obo:HP_0002014","obo:HP_0004396","obo:HP_0011343","obo:HP_0040187","obo:HP_0010913","obo:HP_0000010","obo:HP_0002650","obo:HP_0001276","obo:HP_0001894","obo:HP_0002151","obo:HP_0500001","obo:HP_0000938","obo:HP_0002196","obo:HP_0012402","obo:HP_0030842","obo:HP_0002205","obo:HP_0002751","obo:HP_0010911","obo:HP_0005897","obo:HP_0001270","obo:HP_0001903","obo:HP_0002045","obo:HP_0040181","obo:HP_0002910","obo:HP_0008277","obo:HP_0011185","obo:HP_0005619","obo:HP_0010910","obo:HP_0002176","obo:HP_0002019","obo:HP_0003542"],"previousTesting":true,"previousTestingDescription":"Hemoglobin 1.36 mM (normal 1.4-2.17 mM); 613x10^9 platelets/L (normal 150-400x10^9); glucose 2.16 mM (normal 3.3-5.5 mM). Valine 1026 uM (normal 84.07-354 uM); leucine/isoleucine 829.41 uM (normal 56.82-287 uM).","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/37a63a97-3621-491a-8143-acc4cb23afaa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24486081","allele":[{"id":"https://genegraph.clinicalgenome.org/r/d08af9d9-fe43-4cba-9f8c-1ccff99a3d66","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.1282-4142_*(434_435)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11951"}},{"id":"https://genegraph.clinicalgenome.org/r/e28bbf71-2d6f-462a-ae16-73077d6f49f5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.650dup (p.Leu217PhefsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820832"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/66f0b1ea-1388-44c9-822c-a073041fd498_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Western blot on patient lymphoblasts or fibroblasts: absent E2. This splicing is predicted to result in 21 bp deletion from 5' end of exon 11. Parents were both negative for the variant. A parentage test was ordered and polymorphic SSR analysis at 15 loci on chromosome 1 and 15 loci on other chromosomes confirmed parentage, but found that a de novo mutation arose in the mother prior to meiosis I, followed by nondisjuntion in meiosis II, which resulted in an oocyte with 2 copies of the de novo variant. Upon fertilization by a sperm without chromosome 1 or mitotic loss of chromosome 1 led to the proband inheriting both alleles from the mother.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31b153a2-19ef-4578-9bb5-3b5410ef5b3f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10915611","rdfs:label":"W.J.","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"RT-PCR on total RNA of lymphoblasts, then direct sequencing of the PCR product. Genomic DNA amplified at the intron 10/ exon 11 splice junction followed by direct sequencing.","phenotypeFreeText":"Authors indicate that the patient was diagnosed with the classic form of MSUD type II.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/66f0b1ea-1388-44c9-822c-a073041fd498_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10915611","allele":{"id":"https://genegraph.clinicalgenome.org/r/77c1791c-9b8d-4421-8086-32dc459916ce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.1283_1292del (p.Ala428AspfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820764"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/0aa50cc8-b9c8-403c-95cf-df6f271e5ab2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Consanguinity","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/931af740-77e2-4196-a4e2-fcc990a001db","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28417071","rdfs:label":"DBT-2","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"PCR of coding exons of BCKDHA (9 exons), BCKDHB (11 exons) DBT (11 exons) and DLD (14 exons) followed by sequencing.","phenotypeFreeText":"Patients were identified upon presentation of the clinical symptoms or biochemically by routine newborn metabolic screening of blood spots.","previousTesting":true,"previousTestingDescription":"Biochemical diagnosis was confirmed by liquid LC-MS/MS. Plasma amino acids were also analyzed in suspected MSUD patients.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/0aa50cc8-b9c8-403c-95cf-df6f271e5ab2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28417071","allele":{"id":"https://genegraph.clinicalgenome.org/r/c4e73f0c-0c3d-4450-abc3-f09288b4a8c8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.75_76delAT (p.Cys26Trpfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11950"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9b4da37e-d31c-48c4-b6b6-bb56fe49d5a1_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Consanguinity","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d642797-c394-462d-a6e2-37c4a5dac511","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28417071","rdfs:label":"DBT-1","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"PCR of coding exons of BCKDHA (9 exons), BCKDHB (11 exons) DBT (11 exons) and DLD (14 exons) followed by sequencing.","phenotypeFreeText":"Patients were identified upon presentation of the clinical symptoms or biochemically by routine newborn metabolic screening of blood spots.","previousTesting":true,"previousTestingDescription":"Biochemical diagnosis was confirmed by liquid LC-MS/MS. Plasma amino acids were also analyzed in suspected MSUD patients.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/9b4da37e-d31c-48c4-b6b6-bb56fe49d5a1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28417071","allele":{"id":"https://genegraph.clinicalgenome.org/r/fee5ab66-8c64-4c85-a123-1ad0d3cee264","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.61del (p.Arg21AlafsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820826"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d5c89dc9-3bba-446e-973f-028b1a01b3e4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The predicted mRNA encoded a truncated protein with 282 amino acids, including 4 novel amino acids at the carboxyl terminus. 265bp fragment that included the 126 bp intronic region was subcloned into an exon trapping vector and transfected into COS-1 cells to confirm the splicing defect. Did not score as LOF due to some expression from patient cells in PMID: 3417306.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0998daf6-cd2f-4ce9-91e9-6fbc069e4e91","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9621512","rdfs:label":"KM03","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Total RNA and genomic DNA prepared from lymphoblastoid cells or peripheral leukocytes. RT-PCR was performed with primers in exons 8 and 9 identified an insertion. Gnomic DNA was isolated and sequenced. Confirmed by restriction enzyme digestion.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Diagnosed at the time of newborn screening. Originally presented as classical form, but later determined to be the intermittent form.","phenotypes":["obo:HP_0001254","obo:HP_0002179","obo:HP_0001276","obo:HP_0001263"],"previousTesting":true,"previousTestingDescription":"Lymphoblastoid cells from the patient showed reduced decarboxylation activity: 0.12 nmol/h per mg of protein (~9% of control). The authors previously showed by immunoblot analysis that the level of E2 protein was significantly reduced (PMID 3417306).","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d5c89dc9-3bba-446e-973f-028b1a01b3e4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9621512","allele":{"id":"https://genegraph.clinicalgenome.org/r/c80631ea-8c64-48a1-958d-f6909be7e2ca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.1017_1018insNC_000001.11:g.100207187_100207312","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11946"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/83ce0596-a925-49ae-aa44-e71c6dac623e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5266ad8-f622-42f4-99ff-91031fef761b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22727569","rdfs:label":"Patient 15","ageType":"AgeAtDeath","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Genomic DNA from peripheral blood leukocytes from patients and parents extracted. PCR amplification of exons and intron/exon boundaries for BCKDHA, BCKDHB, DBT.","phenotypeFreeText":"Classic form of MSUD.","previousTesting":true,"previousTestingDescription":"Diagnosed based on elevated blood levels of leucine, valine and the ratio of leucine to phenylalanine (tandem mass spec), as well as abnormal urine BCKAs (gas phase chromatography-mass spec).","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/83ce0596-a925-49ae-aa44-e71c6dac623e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22727569","allele":{"id":"https://genegraph.clinicalgenome.org/r/e4d4b4a1-353b-4302-bc56-4154eaf76b03","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.713del (p.Pro238LeufsTer3)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820836"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/782f71ee-cc49-4653-8a69-ceb30ccaff74_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93c5ab8d-443d-4cf4-a872-78c477d013f9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22727569","rdfs:label":"Patient 13","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":3,"detectionMethod":"Genomic DNA from peripheral blood leukocytes from patients and parents extracted. PCR amplification of exons and intron/exon boundaries for BCKDHA, BCKDHB, DBT.","phenotypeFreeText":"Thiamine-responsive form of MSUD.","phenotypes":["obo:HP_0012758","obo:HP_0008344"],"previousTesting":true,"previousTestingDescription":"Diagnosed based on elevated blood levels of leucine, valine and the ratio of leucine to phenylalanine (tandem mass spec), as well as abnormal urine BCKAs (gas phase chromatography-mass spec).","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/782f71ee-cc49-4653-8a69-ceb30ccaff74_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22727569","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c2423167-75ea-4658-b0dd-1d82e4b59030","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.51+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/94004"}},{"id":"https://genegraph.clinicalgenome.org/r/dbd5b010-0aa4-4f1f-94b6-8481c6fbd568","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.771del (p.Gly258AlafsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820834"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a66c871b-e6c4-410d-b696-5094155f900a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The variant adds 7 amino acids at the carboxyl terminus of the protein. No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/255a6332-d079-4ef7-86ec-52a2e5796be5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9621512","rdfs:label":"KM24","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":7,"detectionMethod":"cDNAs from the patient were amplified, subcloned and sequenced. Confirmed by restriction enzyme digestion.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Newborn screening for MSUD was negative. Diagnosis of intermittent MSUD was established by blood and urine analysis after an illness.","phenotypes":["obo:HP_0002014","obo:HP_0001945","obo:HP_0001254","obo:HP_0002013","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"Lymphoblastoid cells from the patient showed reduced decarboxylation activity (~20% of control).","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a66c871b-e6c4-410d-b696-5094155f900a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9621512","allele":{"id":"https://genegraph.clinicalgenome.org/r/0be985b3-9acd-462b-b851-57cccd406f15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001918.3(DBT):c.1448G>T (p.Ter483Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11947"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ed71a0d6-dfc7-46d1-a107-022c1cb56d8b","type":"EvidenceLine","dc:description":"Gene targeting in mouse ES cells to disrupt the E2 gene. The construct was designed to replace a 1.67kb genomic DNA fragment encompassing part of exon 4 and all of exon 5 with a selectable marker cassette. Targeted ES cells were used to produce chimeric mice who were bred to C57BL/6J mice. Heterozygous mice were used to produce homozygous animals. E2 protein was undetectable in liver and embryonic fibroblasts. Absent BCKDH activity in liver homogenates, reduced blood levels of alanine, glutamate, and glutamine.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64a03f4a-ffdd-4f8e-9010-0b8c00ef6cf6","type":"Finding","dc:description":"All phenotypes listed are consistent with the human disease. The authors used a transgenic strategy to rescue the BCAA elevation  and neonatal lethality by expressing human E2 in the liver which resulted in mice with the intermediate form of MSUD.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16579849","rdfs:label":"Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a1216360-d55d-4e62-985a-a9850b295290","type":"EvidenceLine","dc:description":"ZK669.4 encodes a homolog of human DBT. The ok3001 mutation deletes the 8th exon and part of the 9th, resulting in disruption of the catalytic domain. Non-mammalian model.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1cf278f8-42a3-4d1a-b489-db3793fb98d5","type":"Finding","dc:description":"The deletion resulted in elevated levels of BCAAs, resembling the human MSUD phenotype. They also showed reduced mmBCFAs, which are synthesized from BCAAs.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26683372","rdfs:label":"C. Elegans Models","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b4f08492-1952-47c2-be45-597b5920fde4","type":"EvidenceLine","dc:description":"A mutagenesis screen identified a strain, que, which exhibit a progressive locomotor defect. The authors used a positional cloning technique to identify a single base pair substitution in the splice donor site of exon 6. RT-PCR on RNA from homozygous mutants revealed an altered transcript. The entire 86 base pairs of intron 6 were included, which alters the sequence downstream of Lys268 and has 4 stop codons. Non-mammalian model","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abe8314e-ad8b-4121-be22-7e5567ae3dee","type":"Finding","dc:description":"Elevated BCAA's is a hallmark of MSUD patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22046030","rdfs:label":"Friedrich 2012 Zebrafish Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/691b8cbf-183e-4195-b8c5-ac2149ef516b","type":"EvidenceLine","dc:description":"Lymphoblasts from an MSUD proband and heterozygous parents. The paternal allele produced a transcript with a 124 nucleotide deletion. Maternal allele produces ~50% of the normal amount of mRNA.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59db608a-51ef-4f62-937b-b6e97bf4d202","type":"FunctionalAlteration","dc:description":"BCKD complex activity was determined in the presence of 1 mM alpha-chloroisocaproate and 31 uM 1-[14C]-leucine as substrate. The proband's activity was 2% of wild type, father was 15% of wild type, mother was 35% of wild type.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1990841","rdfs:label":"BCKD Activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cfd1ebde-e447-4877-977e-f5b9fe434adc_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a1d51847-0235-426a-8898-30e7dee84386","type":"EvidenceLine","dc:description":"Well-known disease mechanism. Review: MSUD is caused by decreased function of the BCKAD enzyme complex, which is composed of E1, E2 (encoded by DBT) and E3 subunits. The BCKAD complex is involved in the second step of catabolism of branched-chain amino acids (BCAAs), which are essential for life.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e84c107f-5d15-45d4-9677-5a806e83a927","type":"Finding","dc:description":"Disruption of any subunit of the BCKAD complex leads to an increase and BCAAs, causing toxicity of tissues.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28919799","rdfs:label":"Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":267,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cEZtI-SuQus","type":"GeneValidityProposition","disease":"obo:MONDO_0009563","gene":"hgnc:2698","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_cfd1ebde-e447-4877-977e-f5b9fe434adc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}